Shanghai Eye Disease Prevention and Treatment Center Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2019
NCT03949101
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Jiannan Huang | Shanghai Eye Disease Prevention and Treatment Center | Shanghai Eye Diseases Prevention Treatment Center

Active Ingredients

Drugs in Phase 4 Trials (1)

atropine (8 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease Progression (Phase 4)

Myopia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 1